GOSSELIN MICHAEL L.,FABRIZIO DAVID,SWAIN JOANNA F.,MITCHELL TRACY S.,CAMPHAUSEN RAY,CLOAD SHARON T.,FURFINE ERIC,MORIN PAUL E.,MUKHERJEE RANJAN,TAYLOR SIMEON I.
申请号：
ARP110101521
公开号：
AR081459A1
申请日:
2011.05.03
申请国别(地区):
AR
年份:
2012
代理人:
摘要：
It also provides a Pharmaceutical composition comprising the polypeptide Distribution, a method for Treating Obesity, dyslipidemia, diabetes, hypoglycemia, eating disorders or Cardiovascular Diseases.Claim 1, characterized in that it comprises: a polypeptide of Fibronectin Type III domain to the tenth (10fn3), where the domain 10fn3 joins the domain 1 or 2 of Human Serum Albumin with a KD of 1 mm or smaller, where the average life of Whey polypeptide in the presence of alb u00fa Mine is at least five times greater than the half-life of Serum polypeptide in the absence of Serum Albumin.Claim 5 wherein: a polypeptide comprising a Fibronectin Type III domain of the 10th (10fn3), where the domain 10fn3 binds to human Serum Albumin and comprising an Amino Acid Sequence that is at least 70% identical to SEQ ID no. 2.Claim 6: polypeptide according to claim 5, wherein the 10fn3 Domain consists of one or more of the BC Loop comprising the Amino Acid Sequence shown in SEQ ID no. 5, a Loop comprising the Amino Acid Sequence shown in SEQ ID no. 6 and a FG Loop comprising the Amino Acid Sequence shown in SEQ ID no. 7.Claim 59: wherein a Nucleic Acid encoding a polypeptide according to any one of claims 1 - 26, 45 - 51 or 53, or a polypeptide fusion according to claim 27 - 45 to 52. 61: a claim, characterized in that it comprises a Nucleic Acid vector according to claim 59 or 60.Claim 63: a host Cell which comprises the Vector according to claim 61 or 62.Se provee además una composición farmacéutica que comprende al polipéptido divulgado, un método para tratar la diabetes, obesidad, dislipidemia, hipoglucemia, trastornos alimenticios o enfermedades cardiovasculares.Reivindicación 1: Un polipéptido caracterizado porque comprende un dominio de fibronectina tipo III a la décima (10Fn3), en donde el dominio 10Fn3 se une al dominio 1 ó 2 de seroalbúmina humana con un KD de 1 mM o menor, y en donde la vida media del suero del polipéptido en presencia de albúmina es al menos 5 veces may
